In the future, we will try to collect more clinical samples through multicenter, prospective longitudinal studies to further analyze the clinical value of serum resistin levels in patients with different comorbidities and different disease states of COPD. This evidence concerns the gene RETN and chronic obstructive pulmonary disease.